Bionic Sight’s BS01 Gene Therapy Receives RMAT Designation from the FDA
Company shares preliminary results from Phase 1/2 clinical trial for patients with advanced Retinitis Pigmentosa (RP)NEW YORK, Feb. 18, 2025 ...
Elixirgen Therapeutics Granted FDA Regenerative Medicine Advanced Therapy (RMAT ...
Elixirgen Therapeutics, Inc. is a clinical-stage biotechnology company focused on the treatment of rare diseases and aging-associated diseases using its ZSCAN4 technology and mRNA platform ...